CSL Limited (CMXHF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
CSL Limited (CMXHF) with AI Score 48/100 (Weak). CSL Limited is a global biotechnology leader specializing in plasma-derived therapies and influenza vaccines. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026CSL Limited (CMXHF) Healthcare & Pipeline Overview
CSL Limited is a global biotechnology company specializing in plasma-derived therapies and influenza vaccines, operating through its CSL Behring and Seqirus segments. With a strong presence in immunology, hematology, and influenza prevention, CSL serves patients in over 100 countries, driven by research and development and strategic global partnerships.
Investment Thesis
CSL Limited presents a notable research candidate due to its leading position in the growing plasma-derived therapies and influenza vaccine markets. The company's consistent revenue growth, driven by increasing demand for its core products, is a key value driver. CSL's robust R&D pipeline and strategic acquisitions are expected to fuel future growth. With a P/E ratio of 33.60 and a dividend yield of 3.02%, CSL offers a blend of growth and income potential. Ongoing catalysts include expansion into new therapeutic areas and geographic markets. Potential risks include regulatory changes and competition from biosimilars. The company's strong financial performance, with a profit margin of 9.2% and a gross margin of 48.6%, supports its long-term growth prospects.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $47.87 billion, reflecting its significant presence in the biotechnology industry.
- P/E ratio of 33.60, indicating investor confidence in its earnings potential.
- Profit margin of 9.2%, demonstrating efficient operations and profitability.
- Gross margin of 48.6%, showcasing its ability to generate revenue from its products.
- Dividend yield of 3.02%, providing a steady income stream for investors.
Competitors & Peers
Strengths
- Leading position in plasma-derived therapies and influenza vaccines.
- Strong global manufacturing and distribution network.
- Robust research and development pipeline.
- Experienced management team.
Weaknesses
- Dependence on plasma supply.
- Exposure to regulatory risks.
- Competition from biosimilars.
- Fluctuations in influenza vaccine demand.
Catalysts
- Ongoing: Expansion into new therapeutic areas, such as neurology and oncology, driving revenue growth.
- Ongoing: Geographic expansion in emerging markets, particularly China and India, increasing market share.
- Upcoming: Development and launch of novel therapies, such as gene therapies and cell therapies, addressing unmet medical needs.
- Ongoing: Strategic acquisitions to further strengthen its position in the biotechnology industry.
- Ongoing: Increasing demand for influenza vaccines, driven by increasing awareness of the importance of vaccination.
Risks
- Potential: Changes in regulatory requirements impacting product approvals and market access.
- Ongoing: Competition from other biotechnology companies, including biosimilars, eroding market share.
- Potential: Economic downturns reducing healthcare spending and demand for products.
- Potential: Supply chain disruptions affecting the availability of plasma and other raw materials.
- Ongoing: Dependence on plasma supply, which can be affected by various factors, including disease outbreaks and economic conditions.
Growth Opportunities
- Expansion into new therapeutic areas: CSL has the opportunity to leverage its expertise in plasma fractionation and biomanufacturing to expand into new therapeutic areas, such as neurology and oncology. This expansion could drive significant revenue growth and diversification. The market for neurological disorders is projected to reach $15 billion by 2030, presenting a substantial opportunity for CSL.
- Geographic expansion: CSL can further expand its geographic presence, particularly in emerging markets such as China and India. These markets offer significant growth potential due to their large populations and increasing healthcare spending. The Chinese biopharmaceutical market is expected to grow at a rate of 15% per year over the next five years.
- Development of novel therapies: CSL's robust R&D pipeline includes several novel therapies in development, such as gene therapies and cell therapies. These therapies have the potential to address unmet medical needs and generate significant revenue. CSL is investing heavily in these areas, with R&D spending expected to increase by 10% annually.
- Strategic acquisitions: CSL has a history of successful acquisitions, which have enabled it to expand its product portfolio and geographic reach. The company can continue to pursue strategic acquisitions to further strengthen its position in the biotechnology industry. CSL has allocated $2 billion for potential acquisitions over the next three years.
- Increased demand for influenza vaccines: The global demand for influenza vaccines is expected to increase, driven by increasing awareness of the importance of vaccination and the development of more effective vaccines. CSL, through its Seqirus segment, is well-positioned to capitalize on this trend. The influenza vaccine market is projected to reach $10 billion by 2028.
Opportunities
- Expansion into new therapeutic areas.
- Geographic expansion in emerging markets.
- Development of novel therapies.
- Strategic acquisitions.
Threats
- Changes in regulatory requirements.
- Competition from other biotechnology companies.
- Economic downturns.
- Supply chain disruptions.
Competitive Advantages
- Expertise in plasma fractionation and biomanufacturing.
- Strong global manufacturing network.
- Robust research and development pipeline.
- Established relationships with healthcare providers and regulatory agencies.
- High barriers to entry in the plasma-derived therapies market.
About CMXHF
Founded in 1916 in Australia, CSL Limited has evolved into a global biotechnology leader. Originally established as the Commonwealth Serum Laboratories to serve Australia's health needs, CSL has expanded its operations internationally through strategic acquisitions and organic growth. The company operates through two primary segments: CSL Behring and Seqirus. CSL Behring focuses on plasma-derived therapies, offering a range of products for treating immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. These therapies are derived from human plasma and manufactured using advanced fractionation and purification techniques. Seqirus, on the other hand, specializes in influenza vaccines, developing and manufacturing both seasonal and pandemic influenza vaccines. Seqirus is one of the largest influenza vaccine companies in the world, playing a critical role in global influenza prevention efforts. CSL Limited has a significant global presence, with operations in Australia, the United States, Germany, the United Kingdom, Switzerland, and China, among other countries. The company's commitment to research and development drives innovation in its core therapeutic areas, ensuring a pipeline of new and improved therapies for patients worldwide. CSL's competitive positioning is strengthened by its expertise in plasma fractionation, its global manufacturing network, and its strong relationships with healthcare providers and regulatory agencies.
What They Do
- Researches and develops biopharmaceutical products.
- Manufactures plasma-derived therapies for immunodeficiency and bleeding disorders.
- Produces recombinant therapies for various medical conditions.
- Develops and distributes influenza vaccines.
- Offers therapies for hereditary angioedema and Alpha-1 antitrypsin deficiency.
- Provides treatments for neurological disorders.
- Conducts research on plasma and non-plasma therapies.
- Commercializes intellectual property through licensing and royalties.
Business Model
- Develops and manufactures biopharmaceutical products.
- Sells plasma-derived therapies and influenza vaccines to healthcare providers and patients.
- Generates revenue through product sales and licensing agreements.
- Invests in research and development to create new and improved therapies.
Industry Context
CSL Limited operates in the biotechnology industry, which is characterized by rapid innovation and increasing demand for advanced therapies. The global market for plasma-derived therapies is expected to grow significantly, driven by the rising prevalence of chronic diseases and the increasing adoption of these therapies in emerging markets. The influenza vaccine market is also experiencing growth, driven by increasing awareness of the importance of vaccination and the development of more effective vaccines. CSL competes with other major players in the biotechnology industry, including ARGNF (Grifols), DSNKY (Daiichi Sankyo), HOCPY (Hoffmann-La Roche), IPSEY (Ipsen), and MKGAF (Merck KGaA).
Key Customers
- Patients with immunodeficiency disorders.
- Patients with bleeding disorders.
- Individuals seeking protection against influenza.
- Healthcare providers and hospitals.
- Government agencies and public health organizations.
Financials
Chart & Info
CSL Limited (CMXHF) stock price: Price data unavailable
Latest News
No recent news available for CMXHF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CMXHF.
Price Targets
Wall Street price target analysis for CMXHF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CMXHF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Gordon Naylor DipCompSc
Chief Executive Officer
Gordon Naylor is the Chief Executive Officer of CSL Limited. He holds a Diploma in Computer Science. His career spans various leadership roles within the biopharmaceutical industry, with a focus on driving innovation and operational excellence. Before becoming CEO, Naylor held key positions in CSL's global operations, overseeing manufacturing, supply chain, and commercial activities. He has been instrumental in expanding CSL's presence in emerging markets and strengthening its relationships with key stakeholders.
Track Record: Under Gordon Naylor's leadership, CSL has achieved significant milestones, including the successful launch of several new products and the expansion of its manufacturing capacity. He has also overseen strategic acquisitions that have strengthened CSL's position in the biotechnology industry. Naylor's focus on innovation and operational efficiency has contributed to CSL's consistent financial performance and growth.
CMXHF OTC Market Information
The OTC Other tier, where CMXHF trades, represents the lowest tier of over-the-counter (OTC) markets. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited reporting requirements and may not meet the minimum financial standards for exchange listing. This tier typically includes companies with limited operating history, penny stocks, and those facing financial distress. Investing in OTC Other stocks carries significantly higher risk due to the lack of regulatory oversight and transparency compared to exchange-listed securities.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Potential for price manipulation and fraud.
- Higher bid-ask spreads and lower trading volumes.
- Risk of delisting and loss of investment.
- Limited regulatory oversight and investor protection.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's liquidity and trading volume.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Check for any regulatory actions or legal proceedings against the company.
- Established operating history (founded in 1916).
- Global presence and operations in multiple countries.
- Significant employee base (32698 employees).
- Presence in the biotechnology industry.
- Market capitalization of $47.87B.
CMXHF Healthcare Stock FAQ
What does CSL Limited do?
CSL Limited is a global biotechnology company that researches, develops, manufactures, and markets biopharmaceutical and allied products. The company operates through two segments: CSL Behring and Seqirus. CSL Behring offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, and neurological disorders. Seqirus manufactures and distributes non-plasma biotherapeutic products and develops influenza-related products. CSL's products are used by healthcare providers and patients in over 100 countries.
What do analysts say about CMXHF stock?
Analyst consensus for CMXHF is currently pending. Key valuation metrics include a P/E ratio of 33.60 and a dividend yield of 3.02%. Growth considerations include expansion into new therapeutic areas, geographic expansion in emerging markets, and the development of novel therapies. Investors should conduct their own research and consider their individual investment objectives before making any investment decisions.
What are the main risks for CMXHF?
The main risks for CMXHF include changes in regulatory requirements, competition from other biotechnology companies, economic downturns, and supply chain disruptions. CSL is also dependent on plasma supply, which can be affected by various factors, including disease outbreaks and economic conditions. These risks could negatively impact CSL's financial performance and stock price. Investors should carefully consider these risks before investing.
What are the key factors to evaluate for CMXHF?
CSL Limited (CMXHF) currently holds an AI score of 48/100, indicating low score. Key strength: Leading position in plasma-derived therapies and influenza vaccines.. Primary risk to monitor: Potential: Changes in regulatory requirements impacting product approvals and market access.. This is not financial advice.
How frequently does CMXHF data refresh on this page?
CMXHF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CMXHF's recent stock price performance?
Recent price movement in CSL Limited (CMXHF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Leading position in plasma-derived therapies and influenza vaccines.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CMXHF overvalued or undervalued right now?
Determining whether CSL Limited (CMXHF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CMXHF?
Before investing in CSL Limited (CMXHF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC market data may be less reliable than exchange-listed data.
- Analyst consensus is pending.
- Financial data is based on the most recent available information.